The majority of the studies show a positive correlation between the uptake of PSMA ligands on PET/CT, assessed by semi-quantitative indices, and the expression of PSMA in tissue samples, assessed by IHC, in both primary and metastatic RCC lesions [52,53,61] (Table 3). This evidence concerns the gene FOLH1 and renal cell carcinoma.